Choroidal Neovascularization Market | Industry Insights By Growth, Emerging Trends And Forecast By 2032
The latest report by IMARC Group, titled “Choroidal Neovascularization Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032“, The global choroidal neovascularization market size reached US$ 6.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.4% during 2024-2032.
Choroidal neovascularization (CNV) is a condition marked by the anomalous development of new blood vessels within the choroid layer of the eye, situated just beneath the retina. This ailment is of notable concern in ophthalmology due to its potential to result in significant vision impairment, often associated with age-related macular degeneration (AMD). CNV arises when these aberrant blood vessels breach the Bruch's membrane, a delicate barrier that separates the choroid from the retina, causing the leakage of fluid or blood into the macula—the central region of the retina responsible for clear and precise vision. The accumulation of fluid and blood disrupts the normal macular function, leading to vision distortion or blurring. CNV may present in various forms, including classic CNV, occult CNV, and minimally classic CNV.Choroidal Neovascularization Market Trends and
Drivers:
The market is experiencing notable
advancements and expansion due to the aging demographic in various regions
worldwide. With age-related macular degeneration being a prevalent condition
among older individuals, particularly contributing to CNV, there's a growing
need for effective diagnosis and treatment solutions. As the global population
ages further, the demand for such solutions is anticipated to rise, offering
opportunities for market players. Furthermore, progressions in diagnostic and
imaging technologies are augmenting early CNV detection. Imaging techniques
like optical coherence tomography (OCT) and fluorescein angiography (FA)
facilitate precise and prompt diagnosis, enabling timely interventions such as
anti-vascular endothelial growth factor (anti-VEGF) therapies. Companies
specializing in innovative diagnostic tools and imaging equipment for CNV stand
to benefit from this trend. Additionally, the increasing emphasis on
personalized medicine is impacting the CNV market. Tailoring treatment strategies
based on individual patient characteristics, including genetic predispositions
and biomarkers, is gaining traction. This personalized approach aims to
optimize treatment outcomes while minimizing potential adverse effects.
Moreover, regulatory bodies and healthcare institutions are stressing the
importance of patient accessibility to effective CNV treatments, involving
initiatives to streamline therapy approval processes and enhance reimbursement
mechanisms.
For an in-depth analysis, you can refer sample
copy of the report: https://www.imarcgroup.com/choroidal-neovascularization-market/requestsample
Report Segmentation:
The report has segmented the market into the
following categories:
Breakup by Product Type:
- Intravenous
- Intravitreal
Breakup by Type of Diagnosis:
- Fluorescein Angiography (FA)
- Indocyanine Green (ICG) Angiography
- Spectral Domain Optical Coherence Tomography (OCT)
- Others
Breakup by Treatment Type:
- Angiogenesis Inhibitors Injection
- Photodynamic Therapy
- Laser photocoagulation
- Low-dose Radiation Therapy
- Surgery
Breakup by Application:
- Extreme Myopia
- Malignant Myopic Degeneration
- Age-Related Developments
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia,
Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia,
Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- Bausch Health Companies Inc.
- Bayer AG
- Gilead Sciences Inc.
- F. Hoffmann-La Roche AG
- MaaT Pharma, Novartis AG
- Pfizer Inc.
- Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
- Regeneron Pharmaceuticals Inc.
- Sanwa Kagaku Kenkyusho Co. Ltd. (Suzuken Co. Ltd.).
Note: If you need specific information that is
not currently within the scope of the report, we will provide it to you as a
part of the customization.
About Us
IMARC Group is a leading market research
company that offers management strategy and market research worldwide. We
partner with clients in all sectors and regions to identify their highest-value
opportunities, address their most critical challenges, and transform their
businesses.
IMARC’s information products include major
market, scientific, economic and technological developments for business
leaders in pharmaceutical, industrial, and high technology organizations.
Market forecasts and industry analysis for biotechnology, advanced materials,
pharmaceuticals, food and beverage, travel and tourism, nanotechnology and
novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market
intelligence in the form of research reports, production cost reports,
feasibility studies, and consulting services. Our team, which includes
experienced researchers and analysts from various industries, is dedicated to
providing high-quality data and insights to our clientele, ranging from small
and medium businesses to Fortune 1000 corporations.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 |United
Kingdom: +44-753-713-2163
Comments
Post a Comment